Overview
- Revenue rose 11% to $3.08 billion with adjusted EPS of $4.80, beating expectations as Trikafta drove more than 85% of sales and Trikafta/Alyftrek combined reached about $2.9 billion.
- Alyftrek generated $247 million as analysts pointed to tempered conversion from Trikafta despite the newer regimen’s more convenient dosing.
- Journavx delivered roughly $19.6–$20 million despite more than 300,000 prescriptions and about 170 million covered lives, with pricing, insurance dynamics and free‑drug use cited as sales headwinds.
- Casgevy brought in about $17 million, down more than 40% sequentially, with 50 cell collections and 10 infusions in the quarter highlighting throughput constraints.
- Vertex raised the low end of 2025 revenue guidance to $11.9–$12.0 billion; shares fell after the release before stabilizing as analysts emphasized commercialization execution and upcoming kidney readouts as pivotal.